Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

Company Overview

Amneal Pharmaceuticals, Inc. is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A. In 2018, the acquisition of Impax Laboratories expanded its specialty footprint and R&D capabilities, leading to the creation of Amneal Specialty. The company maintains research centers in New Jersey and India, where teams focus on formulation science, bioequivalence studies and advanced drug delivery technologies.

Amneal’s manufacturing network comprises facilities in the United States, Ireland and India, enabling the company to supply markets across North America, Europe and select emerging regions. Its vertically integrated model extends from active pharmaceutical ingredient (API) production to finished-dose manufacturing, supported by a global quality and regulatory framework. This structure allows Amneal to manage supply chain resilience and maintain cost efficiencies in a competitive generics landscape.

Leadership at Amneal is spearheaded by co-CEOs Chirag and Chintu Modgil, who bring experience in pharmaceutical operations and strategy. The executive team includes President Gregory Divis, overseeing commercial and pipeline functions, as well as a cohort of seasoned professionals in regulatory affairs, quality assurance and global manufacturing. Together, the leadership team aims to drive sustainable growth by expanding product offerings and enhancing patient access to affordable medicines.

Key Stats

• Today's Range: $17.37 to $17.71
• 50-Day Range: $16.69 to $19.10
• 52-Week Range: $9.44 to $19.26
• Volume: 1.43 million shs
• Average Volume: 1.72 million shs
• Market Capitalization: $5.57 billion
• P/E Ratio: 35.59
• Dividend Yield: N/A
• Price Target: $19.00
• Consensus Rating: Buy

Amneal Pharmaceuticals Stock Analysis - MarketRank™

Amneal Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 205th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Buy

Consensus Rating

Amneal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Amneal Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Amneal Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 14.89%

Earnings Growth

Earnings for Amneal Pharmaceuticals are expected to grow by 14.89% in the coming year, from $0.94 to $1.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amneal Pharmaceuticals is 20.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amneal Pharmaceuticals is 20.28, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 213.35.

Price to Book Value per Share Ratio

Amneal Pharmaceuticals has a P/B Ratio of 174.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.60% of the float of Amneal Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 4.89.

Change versus previous month

Short interest in Amneal Pharmaceuticals has recently increased by 14.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amneal Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Amneal Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.13

News Sentiment

Amneal Pharmaceuticals has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Amneal Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 5 people have searched for AMRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amneal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,216,567.00 in company stock.

Percentage Held by Insiders

17.30% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

31.82% of the stock of Amneal Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AMRX
• Previous Symbol: NASDAQ:AMRX
• CIK: 1723128
• Web: amneal.com
• Phone: 908-947-3120
• Fax: 908-947-3146
• Employees: 8,500
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Amneal Pharmaceuticals: $19.00
• High Price Target: $25.00
• Low Price Target: $13.00
• Potential Upside/Downside: +8.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.49
• Trailing P/E Ratio: 35.59
• Forward P/E Ratio: 18.55
• P/E Growth: N/A
• Net Income: $72.06 million
• Net Margins: 5.05%
• Pretax Margin: 6.45%
• Return on Equity: -584.46%
• Return on Assets: 7.78%

Debt

• Debt-to-Equity Ratio: 77.65
• Current Ratio: 2.20
• Quick Ratio: 1.44

Sales & Book Value

• Annual Sales: $3.02 billion
• Price / Sales: 1.84
• Cash Flow: $1.56 per share
• Price / Cash Flow: 11.17
• Book Value: $0.10 per share
• Price / Book: 174.40

Miscellaneous

• Outstanding Shares: 319,350,000
• Free Float: 264,106,000
• Market Cap: $5.57 billion
• Optionable: Optionable
• Beta: 1.24